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Abstract Purpose: We conducted
a retrospective cohort study in an
academic tertiary care center to
characterize ventilator-associated
pneumonia (VAP) in pediatric
patients after cardiac surgery in The
Netherlands. Methods: All patients
following cardiac surgery and
mechanically ventilated for C24 h
were included. The primary outcome
was development of VAP. Secondary
outcomes were duration of mechani-
cal ventilation and length of ICU stay.
Results: A total of 125 patients
were enrolled. Their mean age was
16.5 months. The rate of VAP was
17.1/1,000 mechanical ventilation
days. Frequently found organisms
were Haemophilus inﬂuenzae, Mor-
axella catarrhalis, Staphylococcus
aureus and Pseudomonas aeruginosa.
Patients with VAP had longer dura-
tion of ventilation and longer ICU
stay. Risk factors associated with the
development of VAP were a PRISM
III score of C10 and transfusion of
fresh frozen plasma. Conclu-
sion: The mean VAP rate in this
population is higher than that reported
in general pediatric ICU populations.
Children with VAP had a prolonged
need for mechanical ventilation and a
longer ICU stay.
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Introduction
Ventilator-associated pneumonia (VAP) is deﬁned as
nosocomial pneumonia developing 48 h or more after
initiation of mechanical ventilation. It accounts for 20%
of all nosocomial infections among patients in pediatric
intensive care units (PICU) and has a rate of 2.9–21.6/
1,000 ventilator days [1–3]. Epidemiology and outcomes
of VAP have been extensively researched in adults.
Independent risk factors for VAP include duration of
mechanical ventilation, severity of illness, patient age,
supine head position, previous antibiotic treatment, rein-
tubation, transport out of the ICU, and the use of
histamine-2 blockers [4]. VAP is more common among
adults who have undergone major heart surgery than in
the general population of ICU patients [5].
Fewer data exist for pediatric patients, and most of
these data come from studies of the general PICU popu-
lation. Possible risk factors that have been identiﬁed
include the presence of a genetic syndrome, reintubation,
prolonged duration of mechanical ventilation, prolonged
use of a central venous catheter, enteral feeding and
transport out of the PICU [3, 6–8]. VAP in PICU patients
is associated with adverse outcomes including greater
length of stay, longer duration of mechanical ventilation
and higher mortality [3, 6, 8, 9].
There has been no previous research to characterize
VAP among PICU patients in The Netherlands, and only
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cally at VAP among PICU patients following cardiac
surgery [3, 9, 10]. The objective of this study was
to describe the rates, potential risk factors, and outcomes
of VAP among pediatric patients following cardiac
surgery.
Materials and methods
Setting
The study was conducted in the Leiden University Med-
ical Center (LUMC), an academic tertiary care center.
The PICU is a combined medical surgical ICU that has
eight beds, and admits 400 patients per year.
Patients
All patients admitted to the PICU after cardiothoracic
surgery in 2008 and mechanically ventilated for 24 h or
more were retrospectively identiﬁed and included in the
study.
Standard practice
Patients were intubated with a microcuff tube (high
volume, low pressure) in the operating room. Patients
received 0.5 mg/kg dexamethasone prior to going on
cardiopulmonary bypass. On arrival in the PICU, all
patients were sedated with morphine and midazolam.
Patients did not receive standard neuromuscular block-
ade postoperatively, but only the ﬁrst night if their chest
remained open. All intubated patients had routine daily
chest radiography and were placed in semi-recumbent
position. Sucralfate was given for gastric ulcer protec-
tion while nil by mouth. Pantoprazole was given if
corticosteroids were continued. Oral hygiene was main-
tained by cleaning with wet dental swabs three or four
times daily.
Perioperative antibiotic prophylaxis consisted of
24 h of cefazoline or ﬂucloxacillin if chest closure
was delayed. Empirical antibiotic treatment consisted
of vancomycin and ceftazidime for infants\2 months
of age, and cefuroxim and gentamicin for chil-
dren[2 months of age. When there was a suspicion of
infection, blood and urine were taken for culture.
Endotracheal secretions were obtained using standard
tracheal suctioning and analyzed using semiquantitative
techniques and microscopic qualitative techniques. No
bronchoalveolar lavage was performed or blind tele-
scopic catheters used.
Data collection and study type
Information was retrieved from a prospectively collected
patient data management system (PDMS; iMDsoft,
Needham, MA) including demographic data, cardiac
diagnosis, duration of cardiopulmonary bypass, aortic
cross-clamp time, and Pediatric Risk of Mortality
(PRISM) III score upon admission. The presence of a
central line, an endotracheal tube, a nasogastric/jejunal
tube and their characteristics were recorded, as well as:
medication use, use of blood products, procedures (i.e.
transport out of the PICU, reoperation, delayed chest
closure in PICU, reintubation), duration of ventilation and
PICU length of stay. A more detailed chart review was
performed on all patients in whom there was a suspicion
of infection, as retrospectively deﬁned by the fact that
endotracheal aspirates had been taken. Clinical indicators
of VAP (minimum and maximum temperatures, presence
of purulent sputum, changes in ventilator demands),
microbiology and laboratory results, and chest radio-
graphs were examined. Our institutional review board
waived the need for formal approval.
Deﬁnitions
Nosocomial infection was deﬁned as an infection not
present or incubating at the time of PICU admission with
an onset at least 48 h after admission. VAP was deﬁned as
nosocomial pneumonia in patients receiving mechanical
ventilation developing 48 h or more after initiation of
mechanical ventilation. Primary outcome was diagnosis
of pneumonia based on the Center of Disease Control and
National Nosocomial Infections Surveillance (CDC/
NNIS) criteria (Fig. 1)[ 11].
Worsening gas exchange was deﬁned by an increase in
fraction of inspired oxygen (FiO2), peak inspiratory
pressure (Pip), and/or positive end expiratory pressure
(Peep). PaO2/FiO2 ratios and alveolar–arteriolar oxygen
(A–a) gradients were calculated for patients without car-
diac shunting. The complexity of cardiac surgery was
scored using the risk-adjusted congenital heart surgery
(RACHS-1) system, which ranges from 1 to 6, with
higher scores correlating with more complex surgery and
higher in-hospital mortality [12].
Data analysis
Data were analyzed using SPSS version 16.0. Distribution
of continuous variables was evaluated using the Kol-
mogorov–Smirnov test. Depending on the distribution a
Student’s t test or Mann–Whitney U test was performed.
Categorical variables were compared using the chi-
squared test, and if expected frequencies less than ﬁve
were found in contingency tables Fisher’s exact test was
1657used. All statistical tests were two-tailed. All signiﬁcant
variables (p\0.1) in univariate analysis were further
analyzed using logistic regression analysis.
All patients initially suspected of having an infection
were divided into four groups: (1) VAP, (2) pulmonary
infection that did not fully meet CDC/NNIS criteria for
VAP, (3) nonpulmonary infection, and (4) no infection.
Results
In 2008, a total of 403 patients were admitted to the PICU.
Of these patients, 198 had undergone cardiac surgery of
whom 125 had been ventilated for[24 h and were
included in the study. The patients had a median age of
4.2 months, 54.4% were male, and 82.3% had undergone
an operation on cardiopulmonary bypass. Baseline char-
acteristics are summarized in Table 1. Of the 125 patients
included for review, 91 (73%) were clinically suspected of
havingan infection bythe treatingintensivist (fever,raised
inﬂammatory markers, worsening gas exchange, or puru-
lent sputum) and blood and/or sputum were taken for
culture. In 72 of those suspected of having an infection,
empirical antibiotics were started. Which infections these
patients actually developed were also retrospectively
reviewed. The distribution of the study population is
illustrated schematically in Fig. 2.
Pulmonary infections were the most common noso-
comial infections. Of the 125 patients, 11 (8.8%)
retrospectively qualiﬁed for the diagnosis of VAP, 7
(5.6%) were identiﬁed as having a pulmonary infection
that did not meet the criteria for VAP (they had been
intubated for\48 h at the time of diagnosis), 12 (9.6%)
Fig. 1 Age-speciﬁc criteria for
the diagnosis of pneumonia [11]
(reproduced with permission
from the publisher)
1658developed a central line-related bacteremia (caused by
coagulase-negative staphylococcus in 9 of the 12 patients,
S. aureus in 1 patient and Enterococcus and S. aureus in 2
patients). None of the patients with VAP had positive
blood cultures. Of the 125 patients. 12 (9.6%) developed
another infection (including wound infection, urinary
tract infection, and gastrointestinal infection), and 4
(3.2%) were receiving antibiotic therapy at the time of
admission. None of these patients developed VAP. In 30
patients (24%) no infection developed and antibiotics had
been stopped within 48 h.
The mean VAP rate was 17.1 per 1,000 ventilation
days (11 patients and 644.17 total ventilation days). The
mean time between intubation and diagnosis of VAP was
7.4 days. The most common organism cultured in patients
with VAP was Haemophilus inﬂuenzae, followed by
Moraxella catarrhalis, S. aureus and Pseudomonas
aeruginosa (Table 2).
The results of the univariate analysis comparing
patients with and without VAP are summarized in
Table 3. Patients with VAP were more likely to have had
an admission PRISM score of C10 (p = 0.033), and were
signiﬁcantly more likely to have received one or more
transfusions of fresh frozen plasma (p = 0.050). Aortic
cross-clamp time was longer in the patients with VAP
(mean 90.9 vs. 57.0 min), approaching statistical signiﬁ-
cance (p = 0.056).
All factors with p B 0.1 in the univariate analysis
were entered into a logistic regression analysis (Table 4).
Only a PRISM score C10 was associated with the
development of VAP, with an odds ratio of 4.39 (95% CI
1.06–18.04).
VAP was associated with a longer duration of venti-
lation and longer length of stay in the PICU. Mean
duration of ventilation was 181 h (SD ± 94 h) in patients
with VAP, and 118 h (SD ± 138 h) in patients without
VAP (p = 0.002). Mean length of stay in the PICU was
13.0 days (SD ± 6.8 days) for patients with VAP and
10.4 days (SD ± 10.2 days) for patients without VAP
(p = 0.009). There were no deaths among the patients
with VAP.
Discussion
We performed a retrospective cohort study of VAP in
PICU patients following cardiac surgery. Only a few
previous studies have looked at VAP in this speciﬁc
patient population [3, 9, 10]. This is the ﬁrst study to
characterize VAP in a PICU population in The Nether-
lands. Of the 125 patients included in the study, 11
(8.8%) developed VAP giving a rate of 17.1 episodes of
VAP per 1,000 ventilator days. Fischer et al. [9] found a
comparable rate of 9.6%. Tang et al. [3] reported a
higher incidence of 13% and 21.6 episodes of VAP per
1,000 ventilator days, despite a 3-day prophylaxis with
cefazoline and gentamicin compared to our 24-h pro-
phylaxis with cefazoline. Our use of cuffed tubes might
be an explanation for the lower VAP incidence. Even
though modern microcuffed tubes do not necessarily
provide an isolated airway and tracheal soiling can
probably still occur, in adults the use of cuffed endo-
tracheal tubes has been shown to reduce the incidence of
VAP [13, 14].
Tan et al. [10] reported an even higher incidence of
21.5% for acquired nosocomial pneumonia in children
after cardiac surgery. However, this incidence probably
does not reﬂect the incidence of true VAP, as they did not
comment on the temporal relationship with mechanical
ventilation. Rates reported in general PICU populations
are generally lower than those found in our study:
between 2.9 and 11.6 per 1,000 ventilator days [2, 6].
Higher VAP rates for surgical and trauma ICUs versus
medical ICUs were reported in the 2004 NNIS survey in
both adult and pediatric studies [4, 7, 8, 15].
There is no gold standard for the diagnosis of VAP in
pediatric patients. The diagnostic criteria of VAP remain
contentious. We adhered to the criteria proposed by
Table 1 Study population characteristics (n = 125)
Characteristics Value
Demographics
Male, n (%) 68 (54.4)
Age (months), median (interquartile range) 4.16 (0.52–24.77)
Weight (kg), median (interquartile range) 4.7 (3.50–11.00)
PRISM III score (mean ± SD) 8.2 ± 4.5
PRISM III score C10, n (%) 38 (30.4)
A genetic syndrome, n (%) 18 (14.4)
Previous operation, n (%) 44 (35.2)
Prior antibiotics, n (%) 4 (3.2)
Operation
Use of cardiopulmonary bypass, n (%) 102 (82.3)
Duration of cardiopulmonary bypass (min),
mean ± SD
118 ± 82.1
Aortic cross-clamp time (min), median
(interquartile range)
56 (0–94)
RACHS score (mean ± SD) 2.87 ± 0.95
Procedures, n (%)
Delayed closure of sternum 21 (16.8)
Re-operation 27 (21.6)
Transport out of the PICU 17 (13.6)
Transfusion 114 (91.2)
Total parenteral nutrition 10 (7.9)
Cuffed endotracheal tube 116 (92.8)
Outcome
Duration of ventilation (h),
median (interquartile range)
93 (36.50–145.50)
PICU length of stay (days),
median (interquartile range)
8 (5.0–12.0)
Death, n (%) 3 (2.4)
Number (%) values were normally distributed, median (interquar-
tile range) values were not normally distributed
1659Horan et al. [11] which place an emphasis on identifying a
progressive inﬁltrate in two consecutive chest radiographs
in patients with underlying disease. However, in postop-
erative pediatric cardiac surgical patients it is very
difﬁcult to differentiate between infectious inﬁltrates and
pulmonary over-circulation, ﬂuid overload, atelectases
and pleural effusion on chest radiographs. This indicates
that the criteria proposed by Horan et al. [11] may not be
fully applicable to pediatric patients after cardiac surgery.
Other criteria include worsening gas exchange, reﬂected
in a worsening PaO2/FiO2 ratio and/or an A–a gradient
which are already abnormal due to ﬂuid overload, atel-
ectases or intracardiac shunts in many patients after
cardiac surgery. In our patients with VAP without
shunting (8 of 11) the PaO2/FiO2 ratio decreased by an
average of 16% (from 225 to 188 mmHg) and the A–a
gradient doubled on average from 120 to 249 mmHg.
Further research is needed to address the issue of diag-
nosing VAP, especially in this speciﬁc patient group. We
are currently performing a prospective review of the
incidence of VAP.
The most common etiological agents in VAP in pedi-
atric patients reported previously are P. aeruginosa and S.
aureus [2, 16]. We identiﬁed these bacterial species in 9.1
and 18.2%, respectively. No methicillin-resistant S. aureus
species were identiﬁed. The most commonly isolated
organisms in our population were H. inﬂuenzae (45.5%)
and M. catarrhalis (27.3%), probably representing naso-
pharyngeal ﬂora as associated agents of VAP. All the
cultured bacteria were sensitive to our empirical antibiotic
regimen.Tanetal.[10]alsoreportedgram-negativebacilli
as the most frequent isolates (86.1%), followed by fungi
(7.6%), and gram-positive cocci (6.3%). The incidence of
polymicrobial VAP was 36.4%, similar to that reported by
Srinivasan et al. [7]. No organisms were cultured from the
samples from two patients (18.2%), and rhinovirus was
found by PCR in two patients (18.2%), although it is
unclear what role this played in the etiology of VAP. Of 11
patients with VAP, 9 had positive endotracheal cultures,
obtained by standard endotracheal suction.
Of 76 endotracheal cultures that were taken, 44 were
positive, and 31 patients had positive endotracheal cul-
tures without any clinical signs or symptoms of pulmonary
infection and were retrospectively classiﬁed as coloniza-
tion. However, lower respiratory tract infections often
begin with tracheal colonization that may progress to
ventilator-associated tracheobronchitis (VAT), which can
be diagnosed on the basis of clinical signs (fever, leuko-
cytosis, purulent sputum), microbiological information
(sputum cultures), and the absence of inﬁltrates on chest
403
PICU 
admissions
198
Cardiac surgery
admissions
205
General 
admissions
125 patients
Ventilated > 24 
hours
74 patients
Ventilated < 24 
hours
91 (73%)
Clinically suspected 
infections
34 (27%)
Not clinically 
suspect
72 (58%)
Started on 
antibiotics
19 (15%)
No antibiotics
11 (8.8%)
VAP
7 (5.6%)
pulmonary 
infection 
12 (9.6%)
Central line 
related infection
12 (9.6%)
Other infections 
(see text)
30 (24%)
No infection
Fig. 2 Distribution of study
population
Table 2 Results of the tracheal secretion cultures in the 11 patients
with VAP
Organism No. (%) of patients
a
Haemophilus inﬂuenzae 5 (45.5)
Moraxella catarrhalis 3 (27.3)
Staphylococcus aureus 2 (18.2)
Rhinovirus 2 (18.2)
Pseudomonas aeruginosa 1 (9.1)
Negative cultures 2 (18.2)
a More than one microorganism was cultured in four patients
1660radiographs. VAT can lead to VAP in some patients and
treatment of VAT may be an important factor in pre-
venting VAP [17]. In adult VAP it has also been shown
that appropriate antimicrobial treatment of patients sig-
niﬁcantly improves outcome [4]. It is therefore important
to obtain microbiological information. Protected specimen
brush and bronchoalveolar lavage are recommended to
avoid a high incidence of false-positive endotracheal
cultures due to colonization [4] as they are a good alter-
native to bronchoalveolar lavage [18, 19].
The risk factors found in our study were different from
those reported in general PICU populations (presence of a
genetic syndrome, reintubation, enteral feeding, transport
out of the PICU, duration of mechanical ventilation, and
the presence of a central venous line) [3, 6–8]. In our
study, patients with VAP were more likely to have an
admission PRISM III score of C10 (p = 0.033) as con-
ﬁrmed by multivariate analysis. This could indicate
patients who were more unstable during surgery or
required more complex surgery, which is reinforced by the
fact that they also had longer aortic cross-clamp times.
Tang et al. [3] have reported previously that patients with
complex congenital heart disease are more likely to
develop VAP than patients with simple congenital heart
disease. However, the complexity of cardiac surgery as
deﬁned by the RACHS-1 score did not correlate with
development of VAP in our study (Table 1), a ﬁnding also
reported by Fischer et al. [9]. Furthermore, none of our
patients who developed VAP had delayed sternum closure
compared to 18.4% among the other 114 patients
(Table 3) and steroids were given before cardiopulmonary
Table 3 Characteristics and
outcomes of patients with and
without VAP
Patients with
VAP (n = 11)
Patients without
VAP (n = 114)
p value
Baseline characteristics
Gender (male), n (%) 7 (63.6) 61 (53.5) 0.520
Age (months), mean ± SD 28.8 ± 50.2 15.4 ± 26.3 0.100
Weight (kg), mean ± SD 11.6 ± 12.4 7.7 ± 7.6 0.140
PEISM III score C10, n (%) 7 (63.5) 31 (27.2) 0.033*
A genetic syndrome, n (%) 2 (18.2) 16 (14) 0.66
Pulmonary hypertension, n (%) 5 (45.5) 30 (26.3) 0.289
Previous operation, n (%) 4 (36.4) 40 (35.1) 1.000
Prior antibiotics, n (%) 1 (9.1) 3 (2.6) 0.310
Operation
RACHS score, mean ± SD 2.82 ± 0.98 2.87 ± 0.96 0.981
Use of cardiopulmonary bypass, n (%) 11 (100) 91 (80.5) 0.191
Length of cardiopulmonary bypass (min), mean ± SD 155.3 ± 65.2 114.4 ± 82.9 0.145
Aortic cross-clamp time (min), mean ± SD 90.9 ± 62.5 57.0 ± 53.8 0.056
a
Steroids, n (%) 9 (81.8) 92 (80.7) 1.00
Ventilation, n (%)
Cuffed endotracheal tube 9 (81.8) 107 (93.9) 0.180
Steroids during ventilation 0 2 (1.8) 1.00
Procedures, n (%)
Delayed sternum closure 0 (0) 21 (18.4) 0.209
Reoperation 2 (18.2) 25 (21.9) 1.000
Transport out of the PICU 3 (27.3) 14 (12.3) 0.168
Transfusion, n (%)
Red blood cells 9 (81.8) 98 (86.0) 0.659
Fresh frozen plasma 7 (63.6) 37 (32.5) 0.050*
Platelets 2 (18.2) 22 (19.3) 1.000
Nutrition, n (%)
Total parenteral nutrition 1 (5.6) 9 (8.3) 0.484
Nasojejunal tube 3 (27.3) 13 (11.4) 0.149
Outcome
Duration of ventilation, mean ± SD 181.3 ± 94.4 118.1 ± 138.3 0.002*
Ventilation C72 h, n (%) 11 (100) 62 (54.4) 0.003*
PICU length of stay, mean ± SD 13.0 ± 6.8 10.4 ± 10.2 0.009*
Death, n (%) 0 (0) 3 (2.6) 1.000
* p\0.05
a Value approaching signiﬁcance
Table 4 Logistic regression analysis of factors associated with
VAP in PICU patients
Odds
ratio
95% CI p value
PRISM score[10 4.39 1.06–18.04 0.041*
Transfusion of fresh frozen plasma 1.88 0.46–7.87 0.390
Aortic cross-clamp time (min) 1.01 0.99–1.02 0.132
Age at admission (months) 1.00 1.00–1.00 0.376
* p\0.05
1661bypass to approximately 80% of patients in both groups
(p = 1.00), and neither could therefore be identiﬁed as a
risk factor for VAP. Only two patients received continued
steroids because of low cardiac output syndrome, but
neither developed VAP. However, steroids have been
reported as a risk factor for VAP in the adult literature
[20]. Furthermore, patients with VAP were more likely to
have received a transfusion of fresh frozen plasma,
although in multivariate analysis the difference was not
statistically signiﬁcant. Unfortunately, our numbers were
too small to comment on the temporal relationship
between fresh frozen plasma transfusion and the devel-
opment of VAP. An increased risk of infections in patients
treated with fresh frozen plasma has been reported previ-
ously in adult ICU patients [21].
The age of the patients with VAP was higher (mean
28.8 vs. 15.4 months), although this was not statistically
signiﬁcant. Further analysis did not identify a speciﬁc age
group at risk. Colonization of the upper airway in the
normalpopulationchangeswithage,butwhetherthisplays
a role in the development of VAP needs to be further
investigated. We maintain oral hygiene with oral swabs
using water. Whether chlorhexidine mouthwash would
lower the incidence of VAP is the subject of further
investigation. Preventive interventions based on evidence
in adult settings [22] have been shown to lead to a reduc-
tion in the incidence of VAP in pediatric patients [23, 24].
Patients with VAP had signiﬁcantly prolonged mechanical
ventilation and PICU length of stay. This has also been
reported in previous studies [6, 8, 9]. There were no deaths
in the group of patients with VAP. Only a few studies in
pediatric patients have demonstrated a signiﬁcantly higher
mortality rate in patients with VAP [3, 25]. Higher mor-
tality due to VAP in adults is well documented [26].
The limitations of our study include the fact that it
reﬂects a single-center experience, which may limit its
generalizability. Due to the explorative character of this
study, a formal power analysis was not performed.
Because it was a retrospective study, the data collected
could have been incomplete. However, all our data were
prospectively gathered in our PDMS and were available
for all patients. Possible misclassiﬁcation was addressed
by using very speciﬁc deﬁnitions. Therefore underesti-
mation of our VAP rate, although possible, seems
unlikely. However, the lack of a gold standard for the
deﬁnition of VAP may limit the accuracy of the correla-
tion with risk factors and outcomes. Despite these
limitations the study has allowed us to establish a solid
reference point for VAP in PICU patients in The Neth-
erlands, and has provided us with valuable information
for the setting up of future prospective studies.
Conclusion
VAP in pediatric patients following cardiothoracic sur-
gery is a signiﬁcant problem with longer duration of
mechanical ventilation and longer PICU length of stay.
Conventional criteria might not be fully applicable. The
only independent risk factor was a PRISM score of C10
on admission. Large prospective studies are needed to
further evaluate the diagnostic criteria, risk factors and
interventions which may reduce the incidence of VAP in
this patient group.
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